giving space to the untreated cells, which will then require further additional therapy. Studies have confirmed that stopping first line targeted therapy "even after its failure" causes increase in tumor size and activity [11] . This example specifically relates to Erlotinib therapy in NSCLC, where that current data suggests continuing the treatment even when a patient has failed to respond [12] [13] [14] . To the standard current practice of conventional oncology this is unacceptable, as a physician is asked to continue a therapy when it has already failed, and ask the patient to tolerate the major toxicity involved with these therapies, just because there is no other real option. This dilemma has forced researchers to attempt to develop new treatments including second generation and third generation tyrosine kinase inhibitors (TKIs). These therapies are unable to provide a solution to the cause of the problem: heterogeneity of the tumor. There have been strategies around "sequential tyrosine kinase inhibition" which are intended to reduce the potential and strongly possible effect of secondary mutations in DNA, confirmed by post-therapy circulatory tumor DNA (ctDNA) assessments when a targeted therapy is used. The best example is using the TKIs when pre-treatment circulatory tumor cell (CTC) analysis shows single alteration, and post-treatment CTC analysis shows a wide range of mutations, confirming the fact that the drug itself has promoted heterogeneity of the tumor, on its genomic and epigenomic level [15] [16] [17] [18] .
The other reason that EGFR blockade is questioned has to do with the fact that EGF is involved in STAT regulation, which contrary to understanding of many, upregulates the cyclin dependent kinase and has pro-apoptotic effect, as well as increased caspace [19] . This concept was shown in prior studies that showed activation of EGFR could enhance apoptosis. Conversely the inhibition of EGFR can cause resistance to apoptosis, which is why the combination of cytotoxic therapies has failed to improve survival when added to the EGFR blockade in NSCLC in every trial [19] [20] [21] [22] .
Here we implement a new strategy to use a "heterogenous" approach for a heterogenous tumor. In this approach we have looked in the literature already published in systemic reviews for the mechanisms of resistance in targeted therapies and we have identified following facts:
1) The resistance of a tumor, by selective pressure phenomenon is a common end result of using any and all TKI's [20] [21] [22] [23] .
2) The resistance of the tumor correlates with the patients' survival and is reflected by the circulatory DNA mutational analysis [17, 24, 25] .
3) The strategies of current standard of care to resolve the resistance (such as TKI sequential therapies) has failed, in fact:
The current standard of care induces "heterogeneity" of the tumor, by three mechanisms: first by inducing hypoxia (mainly by cytotoxic therapies) [26] , second by DNA mutation and epigenetic alterations of the DNA [18] , and thirdly through negative impact on cancer stem cells by increasing their plasticity (increased epithelial-mesenchymal transition, or EMT) [27] [28] [29] .
To overcome the above problems, we consider following:
We consider using a multi-targeted approach rather than one target therapy. This approach may replace current best standard of care for heterogenous tumors, where the current recommendations are sequential targeted therapy [30] . Instead of using different targeted therapies at different times, we used several targeted therapies at once. This approach has also been suggested by a few researchers in the field. An example was using Erlotinib with Everolimus compared to Erlotinib alone in Lung CA [31] [32] [33] . Unfortunately the study failed to show any improved survival. The conclusion was that perhaps the EGFR blockade bypassed the mTOR blockade, or there were other downstream targets that were activated by time, besides the mTOR, such as MAPK kinase. There was also a possibility of activation of feedback loops by using mTOR inhibitors themselves. If this is true, it again confirms our theory that using a targeted therapy can (and most likely will) induce the upstream molecules/genes, as well as parallel transduction pathways [31] [32] [33] .
The question we attempt to address is which targets need to be modified to be able to minimize the negative impact on tumor resistance while at the same time avoid the oncogenic addiction pattern. We started to look at the upstream targets, rather than downstream targets, as the more a target is downstream, the more likely to create a negative feedback loop [5] .
The discovery of feedback loops and the activation of upstream targets pointed again to the reasons for lack of long term survival benefit in most patients when a single target was treated alone. Unfortunately all the upstream targets are still under investigation for development of new drugs, and many of them are not yet approved. In lung cancer it is been suggested that the HSP-70 and -90 are a primary target for both resistance to EGFR blockade as well as ERBB2, Akt, and HIF [34] [35] [36] . These drugs yet have not been able to provide an effective tool to overcome resistance in large studies and their high toxicity profile has limited their use. It is worth noting that the combination of targeted therapies such as EGFR and VEGF blockade, in case of lung cancer using Erlotinib and Pazopanib or bevacizumab although exciting in the early stages, [37, 38] have also failed to translate in a significantly higher survival in many trials when compared to the standard of care, which is in contrast to our hypothesis. However we explain that this failure due to two reasons, one the fact that the combination therapy is missing to change the tumor's epigenetic profile, and as discussed earlier negatively impact the genomic stability of the tumor, and secondly the fact that these drugs, although multitargeted in nature, they are not adapted to the mutation allele fraction (MAF) of the tumor, as they are given blindly. Even the combination of these drugs that ultimately blocks all pathways have failed in trials to improve survival, as based on our theory, the ratios for the blockage is more important than the number of targets. In other words, if the tumor is driven by BRAF, and at the same time, has mTOR and KRAS mutations, inhibiting all these targets would perhaps be unnecessary and in fact detrimental as it can cause selective pressure on the other existing cells and activate feedback loops. For example, recent studies have shown that ultimately all colon cancers are RAS positive in a certain ratio, and that targeting EGFR positive cells only increases the growth of KRAS positive minorities [39] . Therefore a multitargeted approach, which consists of targeting the main upstream genes to avoid resistance and activation of upstream genes was initially thought to be reasonable. An example that attempts to overcome this problem is the combination of HSP-70 and -90 inhibitors with EGFR blockade. It has been suggested in the literature using Geldanamycin after erlotinib failure in NSCLC may work by inhibiting HSP-90. [40, 41] . Another example of targeted therapy failure has been shown in KRAS positive cancers. [42] . Due to frequent mutations in lung, pancreatic, and colon cancer, KRAS offered a good theoretical therapeutic target. Tipifarnib, an inhibitor of farnesylation of RAS protein, failed in clinical trials [43] . BRAF inhibition was not much better. The oral multikinase inhibitor, regorafenib, inhibits BRAF and VEGFR, PDFRβ, FGFR, KIT and RET. Drug resistance, however, occurs early which is supported by loss of function of PTEN and activation of AKT. Additional mechanisms of resistance to BRAF inhibitors include secondary KRAS mutations and activation of MEK/ERK [44] . The MEK inhibitor selumetinib produced encouraging results, but caused resistance through up-regulation of WNT signaling [45] .
The end result is that the ratios of the driving mutated cells with actionable targets determine what drugs need to be used. Based on our theory, unnecessarily blocking the targets that are not drivers would enhance resistance.
Therefore:
1) Before using any TKI, (we do not recommend in addition to cytotoxic chemotherapies for reasons explained) we identified the driving mutations. We suggest using ctDNA, as it can guide the possible driving cells through identification of the MAF. Here we could see that assessment of the tumor signature by using circulatory DNA is a useful method, as it can give a snap-shot of the mutations in real time, and also provides a prognostic value for the therapy's effectiveness. Based on our work, the tumor targets are identified, their ratio of penetrance calculated, and the therapy designed to have a real effect on the most relevant cells with minimum effect on the feedback loops. Using the minimum dosage of the targeted drug, (for example in NSCLC with EGFR positivity) we have shown using 1/16 of the standard dosage is effective. The rationale is that the anti-EMT response and CSC response by TKIs are NOT dose dependent. We use targeted therapies at this low dose only as a measure to reduce oncogenic addiction, keeping in mind that we avoid inducing tumor selective pressure at all times. Epigenetic therapies are indeed extremely important to achieve this. In the case for EGFR blockade, we now know that the EGFR target when methylated does not respond to the EGFR blockade and therefore epigenetic demethylation of EGFR is vital to the response to EGFR TKI, [46] and prolongs the response much beyond the estimated 12 months in the trials. In fact we reverse the potential failure of such drugs substantially.
2) Second we attempted to the tumor's heterogenous features by modifying its behavior. We were especially interested in the targets that are involved with the heterogeneity of the tumor. We found that more hypoxic tumors disseminate more ctDNA [47, 48] . The more hypoxic a tumor, the more heterogeneity is seen. Therefore we were interested in regulating the intratumoral hypoxia through epigenetics. In concert with this we identified a major target: HIF-1 and 2, and we designed the MTET therapy around the epigenetic regulation of HIF. Here we have shown in vitro studies to prove our concept by looking at the HIF and tumor integrity in 3-dimensional culture media, and proving the effectiveness of the MTET over HIF related pathways and response elements.
By changing the tumor's behavior, by reducing the tendency for "genometastasis" [49, 50] and dissemination of the tumor's signature through CTC and c DNA, we reduce the tumor's ability to metastasize. It is well studied in cardiovascular research that the cellular dissemination of c DNA is a trigger for stem cell plasticity and inhibits the differentiation of such cells to adipocytes [16] . This process is related to the activation of TLR 7 and 9 (Tolllike receptor 7 and 9) which occurs when the c DNA is globally hypomethylated [51] . The c DNA that is aberrantly methylated can mimic pathogens, and is recognized by the immune system as a target for activation and further catastrophe of immune related cancer stem cell activation by microenvironmental influence. It has also been shown that the hypomethylated (or CpG hypermethylated) DNA can penetrate into the normal distant cells and act as a virus to infect the normal cells as a new host for the cancer, which could then colonize into a new metastatic lesion [50, 51] .
It is mentioned earlier that our approach based on new understanding of cancer biology is revolutionary as it contradicts current standard of care, which is more a phenotypical therapy, as we know all cytotoxic therapies and majority of targeted therapies increase the heterogeneity of the tumor and its behavior. Studies have confirmed that presence of ctDNA alternates with the use of cytotoxic drugs, yet can be used as a marker for response to the therapy [52] . All trials so far (such as S O500) have failed to prove a strategy around targeting the CTC by switching the chemotherapy regimens in breast cancer for example [53] . The rationale behind this certainly is related to increased epithelialmesenchymal transition and hypoxia related expressive genes after cytotoxic therapies in general.
The failure of the current targeted therapies may have to do with the non-adaptiveness of such a method, where the tumor genetic instability causes a very dynamically transforming signature that can only be effectively treated if this instability is reduced (by epigenetic therapy). It has been suggested that targeting heterogeneity at the epigenomic level represents an effective strategy in the treatment of cancer and monitored by its signature (DNA methylation) in ctDNA [51, 54] as emphasis on the pattern of system evolution rather than specific pathways provides a global and more meaningful approach. This is also important in relation to current subject of discussion for tyrosine kinase resistance. The rapid kinetics, the reversibility of acquired drug resistance and the absence of genetic mutations suggest an epigenetic basis for drug insensitivity. Therefore the multitargeted approach should also target the epigenetic targets, to enhance stem cell differentiation and reduce the heterogeneity as well as drug resistance. This plasticity has been described [55] as required for evolution of cancer stem cells during tumorigenesis that can involve movement between cell populations in a reversible fashion. Epigenetic plasticity could impact altered genetic expressions, in the creation of cellular heterogeneity in cancers of all types. Further a reversed epigenetic modification that can correct the aberrancies may reduce the "stemness" of such multipotential cells to a more defined clonogenicity, and lead to reduction in dynamic heterogeneous tumor cell population state. Such genomic architecture changes are modifiable even after genetic and epigenetic mutations have occurred. It is also important to know that heterogeneity is also seen in epigenetic signature of tumors.
Results and Discussion
Here we review thirteen (13) cases of NSCLC and review their outcome. 12 patients with the diagnosis of Stage IV lung adenocarcinoma, and one case of squamous cell carcinoma, all refractory to the current standard of care. We will discuss in detail three cases of lung adenocarcinoma with and without EGFR positive status resistant to standard of care, who we treated successfully with this approach, known as Multitargeted Epigenetic Therapy (MTET). Each patient received MTET therapy per protocol, which is a combination of natural polyphenols injected intravenously. These natural polyphenols have a synergistic effects, and when given in combination, target epigenetic marks such as DNA methylation and histone deacetylation. Therapeutic dosages were customized for each patient, based on factors such as drugs metabolism (after testing of CYP450 and other CYP enzymes), as well as body weight. Our evaluation of Natural Killer cell activity as a marker for immune function did not correlate with therapy related response.
The clinical findings and results were far beyond the expectation in majority of the cases. Most of these patients did not receive any concurrent chemotherapy, except in three cases, where palliative chemotherapy was combined with their treatment. We followed the response through the discussed prognostic markers for survival and following results were obtained:
1) Improved quality of life, 12/13 patients had improved quality of life based on their function and ECOG score. One patient who had no change in ECOG was receiving chemotherapy.
2) Improved plasma VEGF/IL-8: All cases with increased angiogenesis markers responded to the treatment with reduced plasma VEGF/IL-8. The magnitude of response was parallel to the reduction of the tumor markers. There were nine cases with increased VEGF and all dropped to normal levels in a quick fashion, over two weeks of treatment.
3) Improved imaging: Improved imaging was seen in Two cases with brain metastasis, one, refractory to multiple sessions of radiation responded with imaging confirming stable disease after three months under therapy.
4) Improved tumor markers (CYFRA 21.1, FGF-2, CEA):
All cases with increased tumor markers (ten cases) responded to the treatment, with significant reduction of the tumor markers. Average reduction was noticed in 2 weeks of therapy.
5) Improved circulatory tumor cells/circulatory tumor
DNA: all cases with positive CTC or ctDNA responded to the treatments, with complete disappearance of the CTC from the blood. The CTC samples were positive for Histone deacetylase and DNA methyl transferase overexpression, as well as CK19, telomerase and c MYC. Samples were negative post-therapy. Median duration of treatments was 10 days. Circulatory tumor DNA in two cases were obtained, and showed positive mutations in P53/KRAS/ ROS1 and cMET. The tests were repeated after 21 days and showed reduction of the MAF on the altered genes. In one case the KRAS ctDNA decreased, in the other case the ctDNA completely resolved. The altered marker was BRCA2, which disappeared post therapy. Duration of therapy was 16 days. None of these cases received chemotherapy. 6) Overall Survival: Three cases that received concurrent cytotoxic chemotherapy had poor outcome. They passed away after sessions of therapy or could not continue the palliative chemotherapy due to the side effects. One patient who stopped the treatment also passed away in less than 12 months, as was treated with a targeted therapy. The rest of the patients (nine cases) lived beyond their expected life expectancy. Out of 10 patients with Stage IV refractory disease, only one died in less than 12 months. 90 percent of treated patients, who continued care, lived beyond expected life expectancy. 6 patients are still alive 3 to 7 years after their diagnosis and treatment of Stage IV lung cancer. The markers which were positive before starting the treatments were negative after therapy. cMYC and Histone deacetylase markers were normalized. This proves that MET therapy targets include cMYC and HDAC (Case 1).
The circulatory tumor cell analysis was repeated on 4/9/15 after missing two weeks of treatment, and the results show that although the cMYC was still negative, the CTC appeared with lower expression of CK19, and it was concluded that the tumor cell burden in the blood was low. These results prove that the epigenetic therapies were able to maintain the negative cMYC after two weeks, however the dissemination of CTC's would appear with less intensity and tumor burden after two weeks of cessation of treatments. It was also noticeable that the presented CTC's in the blood sample did not have overexpression of EGFR, confirming that the response was not related to the prior treatment with Erlotinib. The patient started the treatments again on a daily basis. On 6/9/15 the PET/CT was repeated and showed resolution of previously described prevascular node, as well as pulmonary nodule in the posterior right lobe, with minimum residual disease at SUV activity of 1.2. All pulmonary nodules have no FDG activity and there was complete resolution of hilar mediastinal, axillary, and supraclavicular lymph nodes previously described as active.
Case 2
69 year old male with history of stage 3B adenocarcinoma of the lung diagnosed initially in March 2015 after three months of undiagnosed cough. He was treated for tuberculosis and Cryptococcal infection, which were found in bronchoscopy. Malignancy then was identified after a CT guided biopsy of the lung mass, which revealed KRAS/ALK/EGFR negative tumor, with contralateral supraclavicular lymph node. After a month, the patient underwent a brain MRI, which revealed a 4 mm brain mass in the parietal lobe, with associated edema. He was fatigued and complained of cough and was taking TB medications for a latent TB. He also had history of COPD/HTN/ CAD/DM/hyperlipidemia.
The patient was started on IV epigenetic therapies immediately following the initial labs that confirmed he had increased neuron specific enolase and CEA. He received 5 treatments and his labs were repeated which showed improved CEA and LDH. Initial CEA was 68.6 and improved to 55.9, while LDH was 323 and decreased to 306. The patient did not change his diet, nor did he receive any other therapies. His quality of life improved. His labs were repeated after 18 sessions of treatment, which showed substantial reduction in neuron specific enolase from 13. , as well as Sutent taken for 27 days and discontinued due to severe side effects in June 2013. The patient was referred to us for evaluation and IV epigenetic treatments in March 2014, and was started immediately after lab were drawn, which showed increased CEA (as a prognostic marker for NSCLC) which was 17.9, dropped to 17.0 after four treatments, received over one week. The patient's FGF-2 was also checked, which showed response to treatment when it dropped to 15.8 from 18.9, measured on 3/12 and 4/1/14 respectively. It further dropped to 4.7 on 4/23/14 after three more weeks of treatment. The patient had a restaging PET scan on 5/20/14, which confirmed decreased metabolic activity of the tumor in all thoracic and chest lesions. The abdomen and pelvis had stable disease, with maximum SUV activity reported at 4.8 from gastrohepatic ligament (from 3.3). There was an unchanged T12, bone lesions in thoracic spine, compared to prior PET. The supraclavicular (5.77 to 3.7, and 3.1 to 2.2), as well as hilar (3.3 from 3.5, and 2.9 from 4.1), mediastinal (4.3 from 7.6) and paratracheal thoracic LNs (4.6 to 2.1) all responded to the treatment, with decreased posterior cervical completely resolved. Left pleural thickening and nodule completely disappeared.
Further she continued the treatments at our clinic, with documented stable to improved disease in her restaging scans. All her thoracic disease improved to almost no significantly FDG avid disease and her peritoneal metastasis was stable to improved.
This represents a positive response in a patient with stage four disease to Epigenetic treatment, refractory to chemotherapy/ and immune therapy. This patient continues our therapy with no reported toxicity on maintenance program.
Conclusion
The clinical application related to the scientific rationale discussed in this article provided clinical benefit beyond expected in traditional setting defined by historical and comparable data in a subset of patients with heterogenous disease. Further hypothesis can be generated based on these preliminary findings, aiming at improving patients' survival in refractory and heterogenous disease.
